{
    "id": 11253,
    "fullName": "KIF5B - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIF5B-ALK results from the fusion of KIF5B and ALK, demonstrating constitutive ALK phosphorylation, increased cell proliferation and migration in culture (PMID: 21656749). KIF5B-ALK fusions have been identified in lung cancer (PMID: 21656749, PMID: 21757253).",
            "references": [
                {
                    "id": 3585,
                    "pubMedId": 21656749,
                    "title": "A novel KIF5B-ALK variant in nonsmall cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21656749"
                },
                {
                    "id": 11198,
                    "pubMedId": 21757253,
                    "title": "ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21757253"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3799,
        "geneSymbol": "KIF5B",
        "terms": [
            "KIF5B",
            "HEL-S-61",
            "KINH",
            "KNS",
            "KNS1",
            "UKHC"
        ]
    },
    "variant": "KIF5B - ALK",
    "createDate": "09/01/2015",
    "updateDate": "04/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing KIF5B-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11292,
                "profileName": "KIF5B - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15388,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIF5B-ALK demonstrated decreased response to Lorbrena (lorlatinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11292,
                "profileName": "KIF5B - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15387,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ensartinib (X-396) inhibited growth of transformed cells expressing KIF5B-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11292,
                "profileName": "KIF5B - ALK"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15385,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIF5B-ALK demonstrated decreased response to Xalkori (crizotinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11292,
                "profileName": "KIF5B - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13576,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing KIF5B-ALK in culture (PMID: 22912387).",
            "molecularProfile": {
                "id": 11292,
                "profileName": "KIF5B - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3653,
                    "pubMedId": 22912387,
                    "title": "Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22912387"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11292,
            "profileName": "KIF5B - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 6477,
                    "name": "ALK Inhibitor",
                    "profileName": "KIF5B - ALK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}